Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C5AR1 | P21730 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5135007 | 0.89 | ALDH1A1 (0.35) | C5AR1ALDH1A1KDM4EPKMHPGD | |
| SCHEMBL5135665 | 0.87 | CASR (0.38) | C5AR1BCHEACHETSHR | |
| SCHEMBL5135552 | 0.87 | LMNA (0.37) | C5AR1BCHE | |
| SCHEMBL5135308 | 0.87 | C5AR1 (0.41) | C5AR1ALDH1A1KDM4EPKMHPGD | |
| SCHEMBL5135460 | 0.85 | C5AR1 (0.36) | C5AR1ALDH1A1KDM4EHPGDHRH3 | |
| SCHEMBL5169689 | 0.85 | C5AR1 (0.40) | C5AR1ALDH1A1KDM4EPKMHPGD | |
| SCHEMBL5137350 | 0.84 | CYP1A2 (0.44) | C5AR1ALDH1A1 | |
| SCHEMBL5137844 | 0.84 | C5AR1 (0.40) | C5AR1ALDH1A1KDM4EPKMHPGD | |
| SCHEMBL5134950 | 0.84 | C5AR1 (0.45) | C5AR1BCHEALDH1A1KDM4EPKM | |
| SCHEMBL5135155 | 0.83 | C5AR1 (0.42) | C5AR1ALDH1A1KDM4EPKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1490044-A4 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORP (US) | 2008-04-16 | — | — | EP | disclosed |
| EP-1490044-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2003084524-A1 | COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS | NEUROGEN CORPORATION (US) | 2003-10-16 | — | — | WO | disclosed |